In a nutshell This study examined outcomes for patients with chronic lymphocytic leukemia (CLL) who discontinued treatment with ibrutinib (Imbruvica). Researchers found that patients who discontinued due to progressive CLL had better survival compared with those who had disease transformation. Some background Ibrutinib is a Bruton tyrosine kinase...
Read More
In a nutshell This study examined lenalidomide (Revlimid) as a consolidation strategy in patients with chronic lymphocytic leukemia (CLL) who have residual disease after treatment. This study reported good response improvements (in 45% of patients with residual disease). Lenalidomide may be particularly suited as a consolidation strategy after...
Read More
In a nutshell This study compared the effectiveness of two types of tyrosine kinase inhibitors – imatinib (Gleevac) and radotinib (Supect) – for chronic myeloid leukemia (CML). Researchers concluded that response to treatment occurred sooner and more strongly with radotinib than with imatinib. Some background Tyrosine kinase...
Read MoreIn a nutshell This study examined a side effect called pleural effusion (PE; fluid build-up in the lungs) in patients with chronic myeloid leukemia (CML) treated with dasatinib (Sprycel). PE occurred in 23% of patients. This study concluded that reducing the dose of dasatinib after the first occurrence of PE did not prevent a recurrence. Some...
Read MoreIn a nutshell This study examined whether the presence of liver dysfunction affects the outcomes of newly diagnosed chronic lymphocytic leukemia (CLL). Researchers concluded that patients with liver dysfunction at diagnosis (about 1 in 25 patients) have shorter survival compared to patients with normal liver function. Some background In CLL, high...
Read More
In a nutshell This study examined the use of thiotepa-based conditioning before stem cell transplantation in acute lymphoblastic lymphoma (ALL). This study concluded that this treatment may be as effective as the currently used conditioning combination. Some background Before undergoing a stem cell transplant, patients must undergo conditioning....
Read MoreIn a nutshell This study reviewed evidence on patients with chronic lymphocytic leukemia (CLL) that stop responding to ibrutinib (Imbruvica) therapy. Some background Tyrosine kinase inhibitor therapy is a targeted therapy that blocks signals needed for tumors to grow. This includes the Bruton tyrosine kinase inhibitor ibrutinib. Ibrutinib blocks a...
Read More
In a nutshell This study examined whether adding mitoxantrone (Novantrone) to the treatment combination known as FCR improves outcomes for chronic lymphocytic leukemia (CLL). Researchers reported no significant benefit when mitoxantrone was added to FCR. Some background For physically fit CLL patients, the chemotherapy and immunotherapy...
Read More
In a nutshell This study examined treatment outcomes in patients with blast-phase chronic myeloid leukemia (CML). Authors reported that intensive treatment early followed by stem cell transplantation remains as the most effective approach. Certain patient characteristics and treatment history are significant predictors of outcomes. Some...
Read More
In a nutshell This phase 2 clinical trial will test the safety and tolerability of a nivolumab (Opdivo) and 5-azacytidine (Vidaza) combination with or without ipilimumab (Yervoy) in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by the maximum tolerated dose. This trial is...
Read More
In a nutshell This phase 1/2 clinical trial will test the safety of bortezomib (Velcade) and vorinostat (Zolinza) with standard chemotherapy in treating infants with acute lymphoblastic leukemia (ALL). The primary outcome will be measured by the tolerability to the treatment. The details Bortezomib is a treatment that inhibits the proteasome, a...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of ibrutinib (Imbruvica) with venetoclax (Venclexta) in treating patients with chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the response to treatment. This trial is being conducted at the University of Texas MD Anderson Cancer Center in Houston,...
Read More
